CDC: STD Rates Skyrocket for Fourth Straight Year

CDC: STD Rates Skyrocket for Fourth Straight Year

CDC: STD Rates Skyrocket for Fourth Straight Year

Cases of three common yet treatable sexually transmitted diseases increased for the fourth consecutive year in 2017, the Center for Disease Control said in a report released Tuesday. An estimated 2.3 million cases of chlamydia, gonorrhea, and syphilis were diagnosed in the USA last year, capping a multiyear period of "steep and sustained increases in STDs", said the US health agency. About 45 percent of cases were among young women aged 15 to 24. In 2016, we saw roughly 200,000 fewer cases compared to 2017, and back in 2013, the number was 600,000 less than 2017's figure.

"We are sliding backward", said Jonathan Mermin, director of CDC's National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.

PREVENTION TREATMENT. This trio of STDs can lead to infertility, stillbirths, ectopic pregnancies, and a host of other conditions if left untreated.

Gonorrhea diagnoses increased 67 percent overall (from 333,004 to 555,608 cases according to preliminary 2017 data) and almost doubled among men (from 169,130 to 322,169).

CDC funding for prevention efforts has hovered around $157 million for the past 18 years, Harvey said. "We are in the midst of an absolute STD public health crisis in this country".


Syphilis diagnoses have spiked by 76 percent since 2013, from 17,375 to 30,644 cases, respectively.

Newer drugs that made HIV less lethal and infectious may have contributed to declining condom use - and the increase in STDs in America, Dr. Gail Bolan, head of the CDC's Division of STD Prevention, told NBC News. Gay, bisexual and other men who have sex with men made up nearly 70 percent of primary and secondary syphilis cases where the gender of the sex partner is known in 2017. Gonorrhea is of particular concern to health experts because it is on the verge of becoming untreatable.

Over the years, gonorrhea has become resistant to almost every class of antibiotics used against it. Ceftriaxone (Rocephin) now stands as the only antibiotic to retain high effectiveness against gonorrhea in the United States, the CDC says.

Ceftriaxone is the only remaining effective antibiotic for treating gonorrhea in the United States.

Related news



[an error occurred while processing the directive]